The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

Illumina & Tempus collaborate to drive future of precision medicine through genomic AI innovation: San Diego Saturday, April 19, 2025, 12:00 Hrs [IST] Illumina Inc. and Tempus AI, ...

Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

"In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate ...

Nancy Pelosi’s only profitable 2025 stock, Tempus AI is in radar after insider trading filings revealed over $1.34 million in ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to ...